NasdaqCM - Nasdaq Real Time Price USD

MiMedx Group, Inc. (MDXG)

6.43 -0.08 (-1.23%)
At close: April 24 at 4:00 PM EDT
6.34 -0.09 (-1.40%)
After hours: April 24 at 7:59 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
321,477.00
321,477.00
267,841.00
242,019.00
248,234.00
Cost of Revenue
54,634.00
54,634.00
48,316.00
39,628.00
39,330.00
Gross Profit
266,843.00
266,843.00
219,525.00
202,391.00
208,904.00
Operating Expense
229,727.00
229,727.00
234,252.00
209,389.00
253,275.00
Operating Income
37,116.00
37,116.00
-14,727.00
-6,998.00
-44,371.00
Net Non Operating Interest Income Expense
-6,457.00
-6,457.00
-5,016.00
-4,980.00
-7,941.00
Other Income Expense
-26.00
-26.00
-4.00
-76.00
-9,231.00
Pretax Income
30,633.00
30,633.00
-19,747.00
-12,054.00
-61,543.00
Tax Provision
-36,806.00
-36,806.00
206.00
247.00
-12,259.00
Net Income Common Stockholders
55,796.00
55,796.00
-26,533.00
-18,437.00
-49,284.00
Diluted NI Available to Com Stockholders
55,796.00
55,796.00
-26,533.00
-18,437.00
-49,284.00
Basic EPS
0.40
0.40
-0.33
-0.15
-0.77
Diluted EPS
0.37
0.37
-0.33
-0.15
-0.77
Basic Average Shares
116,495.81
116,495.81
112,909.27
110,353.41
108,257.11
Diluted Average Shares
145,962.46
145,962.46
112,909.27
110,353.41
108,257.11
Total Operating Income as Reported
37,116.00
37,116.00
-14,727.00
-7,051.00
-45,398.00
Total Expenses
284,361.00
284,361.00
282,568.00
249,017.00
292,605.00
Net Income from Continuing & Discontinued Operation
67,439.00
67,439.00
-19,953.00
-12,301.00
-49,284.00
Normalized Income
67,439.00
67,439.00
-19,953.00
-12,262.31
-41,894.22
Interest Expense
6,457.00
6,457.00
5,016.00
4,980.00
7,941.00
Net Interest Income
-6,457.00
-6,457.00
-5,016.00
-4,980.00
-7,941.00
EBIT
37,090.00
37,090.00
-14,731.00
-7,074.00
-53,602.00
EBITDA
40,517.00
40,517.00
-10,685.00
-1,891.00
-46,747.00
Reconciled Cost of Revenue
51,969.00
51,969.00
44,971.00
35,265.00
33,548.00
Reconciled Depreciation
3,427.00
3,427.00
4,046.00
5,183.00
6,855.00
Net Income from Continuing Operation Net Minority Interest
67,439.00
67,439.00
-19,953.00
-12,301.00
-49,284.00
Total Unusual Items Excluding Goodwill
--
--
--
-53.00
-9,228.00
Total Unusual Items
--
--
--
-53.00
-9,228.00
Normalized EBITDA
40,517.00
40,517.00
-10,685.00
-1,838.00
-37,519.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
--
--
--
-14.31
-1,838.22
12/31/2020 - 2/12/2008

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

PTGX Protagonist Therapeutics, Inc.
25.70
-4.28%
 
KROS Keros Therapeutics, Inc.
56.24
+1.90%
 
ZNTL Zentalis Pharmaceuticals, Inc.
11.77
-6.36%
 
ENTA Enanta Pharmaceuticals, Inc.
12.92
-1.75%
 
MLYS Mineralys Therapeutics, Inc.
11.36
-0.61%
 
CGEN.TA Compugen Ltd.
749.50
+4.58%
 
MGNX MacroGenics, Inc.
15.70
-3.27%
 
PCVX Vaxcyte, Inc.
60.30
-0.95%
 
RPTX Repare Therapeutics Inc.
3.3000
-1.79%
 
LGND Ligand Pharmaceuticals Incorporated
71.00
+1.59%